Jim Hoffman: Uncontrolled Neutrophil Activation and NET Release in the Vasculature
Jim Hoffman, Former Technical Advisor at Cygnus Technologies, LLC, posted on LinkedIn:
” ‘We observe extensive spontaneous neutrophil extracellular trap (NET) formation in MIS-C, and we identify neutrophil activation and degranulation signatures. Mechanistically, we determine that SARS-CoV-2 immune complexes are sufficient to trigger NETosis. Our findings suggest that hyperinflammatory presentation during MIS-C could be mechanistically linked to persistent SARS-CoV-2 antigenemia, driven by uncontrolled neutrophil activation and NET release in the vasculature.’ Yonker et al 2022 Neutrophil profiles of pediatric COVID-19 and multisystem inflammatory syndrome in children
Here is a extracorporeal removal therapy developed by https://santersus.com. This therapy is designed to specifically remove and treat the immunothrombotic complications resulting from LC and many other disease triggers worsened by having too many hyperactivated neutrophils/NETs circulating in the blood. Read more here.
Directly targeting the removal of NETs from plasma is proving powerful for the treatment of severe drug-refractory SLE. What about other hyperactivated NETotic-driven diseases like LC PASC/MIS-C or A that display chronic low to intermediate grade NETosis dysregulation?
Your findings of hyperactivated NETosis induction and poor NET clearance are not unique. For more research, visit here.”
Quoting PolyBio Research Foundation’s post:
“PolyBio supports research & treatment for children with Long COVID. This year, a study by our team at Harvard Medical School found that neutrophil immune cells from children with Long Covid were hyperactive and associated with pro-inflammatory pathway signaling.
Circulating spike protein, potentially leaking from SARS-CoV-2 tissue reservoirs, was detected in blood from a subset of children. We are further supporting a clinical trial in Long COVID children, to test if the drug Larazotide can reduce gut barrier permeability, thereby stopping spike leakage into blood.
Learn more about the research that PolyBio is driving forward in our Impact Report”
Get informed with Hemostasis Today.
-
Apr 10, 2026, 16:36José Luis Ferreiro: After Stent Treatment in Heart Attack Patients How to Balance Bleeding and Clotting Risk
-
Apr 10, 2026, 15:54Niccolò Bitto: Answers to Some of the Most Frequently Asked Questions on Gene Therapy for Hemophilia
-
Apr 10, 2026, 15:52Tareq Abadl: Coombs Test Explained in a Simple and Clear Way
-
Apr 10, 2026, 15:10Jecko Thachil: Should We Consider Air Pollution as a Thrombophilic Marker?
-
Apr 10, 2026, 14:02Pablo Corral: Are Cholesterol and Inflammation Really Equal in Atherosclerosis?
-
Apr 10, 2026, 13:43Mohammed Alo։ How Low Should LDL Go in Secondary Prevention of Cardiovascular Disease
-
Apr 10, 2026, 13:21John Abraham: Telomere Biology Disorders – From Bench to Bedside
-
Apr 10, 2026, 01:19Heghine Khachatryan: When Vascular Fragility Defines Risk – Rethinking Hemostasis in LDS
-
Apr 9, 2026, 21:39Mechanisms of Immune Dysregulation in Immune Thrombocytopenia – JTH